Navigation Links
Nycomed's Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Date:10/28/2008

- Both 12-month pivotal studies in patients with symptomatic Chronic Obstructive Pulmonary Disease (COPD) meet primary endpoints

- Data show reductions in moderate and severe exacerbations requiring medical intervention

- Application for marketing authorisation in EU and US expected in 2009

- Partnering process for commercialisation in the US to be initiated

ZURICH, Switzerland, Oct. 28 /PRNewswire/ -- Nycomed today announced encouraging results from a preliminary analysis of four Phase III trials of Daxas(R) (roflumilast) in the treatment of symptomatic COPD. Two pivotal 12-month studies met their primary endpoints, showing effects on exacerbation rates and pulmonary function (FEV1). Furthermore, two supporting six-month studies confirmed the efficacy of Daxas when used with standard bronchodilator treatments. Further analysis including the secondary endpoints is ongoing and full data from all four studies are expected to be published during 2009. In light of the initial data analysis, Nycomed expects to file for European and US marketing authorisation next year. The company will also initiate the process of identifying a partner to commercialise Daxas in the United States.

Commenting on today's announcement, Hakan Bjorklund, Chief Executive Officer of Nycomed, said: "We are extremely encouraged by the positive results from our preliminary analysis of four phase III trials involving more than 4,500 patients. We believe Daxas has the potential to make a significant contribution to COPD management and will therefore be a great addition to Nycomed's product portfolio."

Anders Ullman, Executive Vice President R&D, added: "COPD has a very high morbidity and mortality. Epidemiological data suggest that it is growing at a significant rate all around the world. Daxas is well placed to be the only anti-inflammatory product that specifically targets the inflammatory processes, which appear to play an important role in COPD. Wi
'/>"/>

SOURCE Nycomed
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jellyfish Protein Shows Potential to Help With Memory
2. Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents
3. New carbon material shows promise of storing large quantities of renewable electrical energy
4. Oil palm plantations are no substitute for tropical rainforests, a new study shows
5. Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures
6. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
7. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
8. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
9. Atrium shows a strong financial performance for its first quarter
10. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
11. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... 15, 2014 ­ RedBrick Health , a fast-growing ... today announces that EmblemHealth , the ... is now providing the RedBrick Compass health assessment, combined ... all of its members. EmblemHealth is among the first ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... WALTHAM, Mass., Nov. 2, 2010 Repligen Corporation (Nasdaq: ... second quarter of fiscal year 2011, ended September 30, ... compared to total revenue of $5,421,000 for the second ... or 35%.  Bioprocessing product revenue for the second quarter ...
... Inc. (OTC Bulletin Board: WDST ), a ... therapies to restore the health of damaged tissues and ... newest advancements in regenerative medicine on November 9th, 2010 ... role in the commercialization of the therapeutic candidate, PermaDerm™, ...
... of a Nobel prize this year but research led ... Warwick has found molecular hooks on the surface of ... provide massive benefits to researchers using transmission electron microscopes. ... mechanisms. The research team, which includes Drs. Jeremy Sloan, ...
Cached Biology Technology:Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 2Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 3Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 4Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 5Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 6Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 7Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine 2Pivoting hooks of graphene's chemical cousin could revolutionize work of electron microscopes 2
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... in their blood are more likely to survive the disease, ... of vitamin D have half the risk of dying compared ... The study is the first to correlate total blood levels ... which includes that produced after exposure to sunlight and ... survival prospects. , The University of Edinburgh team tested ...
(Date:7/9/2014)... they are used in the right ways. ... Hospital and coauthors analyzed six use cases with ... decompensation (when a patient,s condition worsens); adverse events; ... organ systems. They suspect that cost-savings benefits will ... all six scenarios will be significant. The authors ...
Breaking Biology News(10 mins):The impact of big data on health care: Health Affairs' July issue 2
... of great whales ever recorded? To answer that ... the Wildlife Conservation Society have joined experts from other ... Commission on the Patagonian coast of Argentina to try ... issue is the long-term conservation of the southern right ...
... "Four and 20 black birds baked in a pie" but ... analysis, means scientists now know there is one more species of ... thought. And if Dr. Gary Voelker has his way, he,ll soon ... deforestation now occurring across its native habitat. The bird ...
... resistance to sea lice treatments such as the pyrethroids ... Pyrethroid use still increased from 2008 to 2009, although ... are being used again due to resistance problems, e.g. ... been used since 1997, was also used again in ...
Cached Biology News:Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3African bird discovery proves there is something new under the sun 2
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: